Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer (CRC) patients.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: patients.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial

Source: Article title.

In an ongoing randomized double-blind, placebo-controlled trial in Germany, CRC patients who underwent surgery in the past year and had serum 25-hydroxyvitamin D levels < 60 nmol/L were randomly assigned to either a personalized loading dose of VIDS, followed by a maintenance dose of 2000 IU/day or a placebo for 12 weeks.

Source: Abstract.

In the placebo group, two participants were excluded because of non-compliance, leaving 63 for per-protocol analysis.

Source: Methods.

Patients and study staff were masked to the group assignment (double-blind trial).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial

Randomised controlled trial · British Journal of Cancer · 2026

Original publication title

Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial

Tafirenyika Gwenzi; Alexander N. R. Weber; Kira Trares; Tomislav Vlaski; Marija Slavic; Sha Sha; Edelmann Dominic; Reiner Caspari; Bettine Bilsing; Harald Fischer; Cristina-Maria Fernandes-Almeida; David Czock; Ben Schöttker; Hermann Brenner

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In CRC patients with low vitamin D status, VIDS reduces serum IL-6, a pro-inflammatory biomarker associated with poor prognosis. Further research should explore a potential supportive therapeutic role of VIDS in managing inflammation and improving CRC outcomes. [Words: 200].

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer (CRC) patients. We assessed the efficacy of personalized vitamin D3 supplementation (VIDS) for reducing inflammation in patients with low vitamin D status.

Source: Background

Abstract: What methods does the paper describe?

In an ongoing randomized double-blind, placebo-controlled trial in Germany, CRC patients who underwent surgery in the past year and had serum 25-hydroxyvitamin D levels < 60 nmol/L were randomly assigned to either a personalized loading dose of VIDS, followed by a maintenance dose of 2000 IU/day or a placebo for 12 weeks. Changes in serum interleukin-6 (IL-6), interferon-gamma (IFN-γ), and matrix metalloproteinase (MMP-1) were compared at the end of trial among 126 patients (65 in the placebo and 61 in the intervention group).

Source: Methods

Abstract: Results

The VIDS group exhibited 39.3% reduction in IL-6 levels compared to the placebo group (95% CI: −54.9% to −18.2%; p = 0.001). The reductions observed in IFN-γ and MMP-1 due to VIDS were not statistically significant (−6.7%; p = 0.69 and −5.4%; p = 0.23, respectively).

Source: Results

Abstract: Conclusion

In CRC patients with low vitamin D status, VIDS reduces serum IL-6, a pro-inflammatory biomarker associated with poor prognosis. Further research should explore a potential supportive therapeutic role of VIDS in managing inflammation and improving CRC outcomes. [Words: 200].

Source: Conclusion
Authors’ abstract

Background

Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer (CRC) patients. We assessed the efficacy of personalized vitamin D3 supplementation (VIDS) for reducing inflammation in patients with low vitamin D status.

Methods

In an ongoing randomized double-blind, placebo-controlled trial in Germany, CRC patients who underwent surgery in the past year and had serum 25-hydroxyvitamin D levels < 60 nmol/L were randomly assigned to either a personalized loading dose of VIDS, followed by a maintenance dose of 2000 IU/day or a placebo for 12 weeks. Changes in serum interleukin-6 (IL-6), interferon-gamma (IFN-γ), and matrix metalloproteinase (MMP-1) were compared at the end of trial among 126 patients (65 in the placebo and 61 in the intervention group).

Results

The VIDS group exhibited 39.3% reduction in IL-6 levels compared to the placebo group (95% CI: −54.9% to −18.2%; p = 0.001). The reductions observed in IFN-γ and MMP-1 due to VIDS were not statistically significant (−6.7%; p = 0.69 and −5.4%; p = 0.23, respectively).

Conclusion

In CRC patients with low vitamin D status, VIDS reduces serum IL-6, a pro-inflammatory biomarker associated with poor prognosis. Further research should explore a potential supportive therapeutic role of VIDS in managing inflammation and improving CRC outcomes. [Words: 200].

Publication and source details

Original title: Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial

Tafirenyika Gwenzi; Alexander N. R. Weber; Kira Trares; Tomislav Vlaski; Marija Slavic; Sha Sha; Edelmann Dominic; Reiner Caspari; Bettine Bilsing; Harald Fischer; Cristina-Maria Fernandes-Almeida; David Czock; Ben Schöttker; Hermann Brenner

British Journal of Cancer · 2026

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Wereld Kanker Onderzoek Fonds (WKOF) grant# IIG 2018/1696

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:50:43.664853+00:00

DOI: 10.1038/s41416-025-03333-6 · PMC12960710